Compare KBH & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBH | SRRK |
|---|---|---|
| Founded | 1957 | 2012 |
| Country | United States | United States |
| Employees | N/A | 289 |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.6B |
| IPO Year | 1994 | 2018 |
| Metric | KBH | SRRK |
|---|---|---|
| Price | $54.08 | $40.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $61.70 | $55.10 |
| AVG Volume (30 Days) | 764.0K | ★ 1.1M |
| Earning Date | 03-19-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.15 | N/A |
| Revenue | ★ $4,547,002,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.30 | $449.79 |
| P/E Ratio | $8.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.70 | $22.71 |
| 52 Week High | $68.71 | $49.82 |
| Indicator | KBH | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 29.89 | 34.35 |
| Support Level | $50.16 | $29.32 |
| Resistance Level | $56.50 | $42.54 |
| Average True Range (ATR) | 1.66 | 2.27 |
| MACD | -1.01 | -0.67 |
| Stochastic Oscillator | 11.01 | 7.79 |
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.